OA13012A - Method for the prevention of malaria. - Google Patents
Method for the prevention of malaria. Download PDFInfo
- Publication number
- OA13012A OA13012A OA1200500157A OA1200500157A OA13012A OA 13012 A OA13012 A OA 13012A OA 1200500157 A OA1200500157 A OA 1200500157A OA 1200500157 A OA1200500157 A OA 1200500157A OA 13012 A OA13012 A OA 13012A
- Authority
- OA
- OAPI
- Prior art keywords
- sporozoites
- plasmodium
- vaccine
- host
- pharmaceutical composition
- Prior art date
Links
- 201000004792 malaria Diseases 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 38
- 230000002265 prevention Effects 0.000 title description 2
- 210000003046 sporozoite Anatomy 0.000 claims abstract description 178
- 230000002238 attenuated effect Effects 0.000 claims abstract description 49
- 238000011081 inoculation Methods 0.000 claims abstract description 10
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 10
- 229960005486 vaccine Drugs 0.000 claims description 74
- 244000045947 parasite Species 0.000 claims description 47
- 208000015181 infectious disease Diseases 0.000 claims description 37
- 241000223960 Plasmodium falciparum Species 0.000 claims description 26
- 238000001990 intravenous administration Methods 0.000 claims description 26
- 210000003079 salivary gland Anatomy 0.000 claims description 19
- 241000224016 Plasmodium Species 0.000 claims description 16
- 238000011161 development Methods 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 14
- 241000282414 Homo sapiens Species 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 10
- 230000005855 radiation Effects 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 8
- 230000002440 hepatic effect Effects 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 4
- 241000256186 Anopheles <genus> Species 0.000 claims description 3
- 241000223801 Plasmodium knowlesi Species 0.000 claims description 3
- 241000223821 Plasmodium malariae Species 0.000 claims description 3
- 241001505293 Plasmodium ovale Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 2
- 108010041986 DNA Vaccines Proteins 0.000 claims description 2
- 229940021995 DNA vaccine Drugs 0.000 claims description 2
- 229940022005 RNA vaccine Drugs 0.000 claims description 2
- 108700021021 mRNA Vaccine Proteins 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 210000003494 hepatocyte Anatomy 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 3
- 241000223810 Plasmodium vivax Species 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 229940118768 plasmodium malariae Drugs 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 230000010558 Gene Alterations Effects 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 abstract description 20
- 230000001681 protective effect Effects 0.000 description 32
- 241000699670 Mus sp. Species 0.000 description 30
- 241000255925 Diptera Species 0.000 description 28
- 241000282412 Homo Species 0.000 description 28
- 230000003053 immunization Effects 0.000 description 27
- 241000223830 Plasmodium yoelii Species 0.000 description 25
- 238000002649 immunization Methods 0.000 description 20
- 230000036039 immunity Effects 0.000 description 15
- 241000224017 Plasmodium berghei Species 0.000 description 13
- 238000011725 BALB/c mouse Methods 0.000 description 12
- 238000000432 density-gradient centrifugation Methods 0.000 description 12
- 238000002224 dissection Methods 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 229940124735 malaria vaccine Drugs 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000010253 intravenous injection Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 241000283984 Rodentia Species 0.000 description 7
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000001524 infective effect Effects 0.000 description 5
- 208000002476 Falciparum Malaria Diseases 0.000 description 4
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 210000003936 merozoite Anatomy 0.000 description 4
- 238000013296 A/J mouse Methods 0.000 description 3
- 102100027211 Albumin Human genes 0.000 description 3
- 206010003399 Arthropod bite Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940023143 protein vaccine Drugs 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 229940031626 subunit vaccine Drugs 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101710117490 Circumsporozoite protein Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 241001414900 Anopheles stephensi Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241001442539 Plasmodium sp. Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- XMQFTWRPUQYINF-UHFFFAOYSA-N bensulfuron-methyl Chemical compound COC(=O)C1=CC=CC=C1CS(=O)(=O)NC(=O)NC1=NC(OC)=CC(OC)=N1 XMQFTWRPUQYINF-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002348 hepatitis b surface antigen vaccine Drugs 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000008336 microcirculatory blood flow Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 244000000040 protozoan parasite Species 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42791102P | 2002-11-20 | 2002-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13012A true OA13012A (en) | 2006-11-10 |
Family
ID=32326611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500157A OA13012A (en) | 2002-11-20 | 2003-11-20 | Method for the prevention of malaria. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1563301B1 (de) |
| JP (1) | JP2006508988A (de) |
| KR (1) | KR20050083941A (de) |
| CN (1) | CN1934448B (de) |
| AP (1) | AP1925A (de) |
| AT (1) | ATE524735T1 (de) |
| AU (1) | AU2003294482A1 (de) |
| BR (1) | BR0316423A (de) |
| CA (1) | CA2506696C (de) |
| ES (1) | ES2371066T3 (de) |
| IL (1) | IL168651A (de) |
| NZ (1) | NZ540719A (de) |
| OA (1) | OA13012A (de) |
| WO (1) | WO2004045559A2 (de) |
| ZA (1) | ZA200504053B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA13341A (en) | 2003-12-19 | 2007-04-13 | Seattle Biomedical Res Inst | Live genetically attenuated malaria vaccine. |
| US7722860B2 (en) | 2004-12-03 | 2010-05-25 | Seattle Biomedical Research Institute | Live genetically engineered protozoan vaccine |
| US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
| WO2008094183A2 (en) * | 2006-07-11 | 2008-08-07 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
| CA2822924A1 (en) * | 2010-12-27 | 2012-07-05 | Eng Hong LEE | Roadmap for controlling malaria |
| FR2978048B1 (fr) | 2011-07-20 | 2014-10-10 | Univ Paris Curie | Composition vaccinale contre le paludisme |
| SG11201608935TA (en) * | 2014-05-02 | 2016-11-29 | Sanaria Inc | Infectious plasmodium sporozoites grown in vitro |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2031468A1 (en) * | 1989-12-08 | 1991-06-09 | Mitchell S. Gross | Malaria vaccine |
| US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
| HUP0200302A2 (en) * | 1999-02-18 | 2002-05-29 | Rmf Dictagene Sa | Malaria vaccine |
| US8735329B2 (en) * | 2008-01-18 | 2014-05-27 | Katholieke Universiteit Leuven K.U. Leuven R&D | Markers and diagnostic methods for metastasis |
-
2003
- 2003-11-20 AT AT03789967T patent/ATE524735T1/de not_active IP Right Cessation
- 2003-11-20 KR KR1020057009184A patent/KR20050083941A/ko not_active Ceased
- 2003-11-20 CA CA2506696A patent/CA2506696C/en not_active Expired - Fee Related
- 2003-11-20 AP AP2005003332A patent/AP1925A/xx active
- 2003-11-20 OA OA1200500157A patent/OA13012A/en unknown
- 2003-11-20 ES ES03789967T patent/ES2371066T3/es not_active Expired - Lifetime
- 2003-11-20 WO PCT/US2003/037498 patent/WO2004045559A2/en not_active Ceased
- 2003-11-20 JP JP2004554018A patent/JP2006508988A/ja active Pending
- 2003-11-20 EP EP03789967A patent/EP1563301B1/de not_active Expired - Lifetime
- 2003-11-20 NZ NZ540719A patent/NZ540719A/en not_active IP Right Cessation
- 2003-11-20 AU AU2003294482A patent/AU2003294482A1/en not_active Abandoned
- 2003-11-20 BR BR0316423-3A patent/BR0316423A/pt not_active IP Right Cessation
- 2003-11-20 CN CN2003801075999A patent/CN1934448B/zh not_active Expired - Fee Related
-
2005
- 2005-05-18 IL IL168651A patent/IL168651A/en active IP Right Grant
- 2005-05-19 ZA ZA200504053A patent/ZA200504053B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2371066T3 (es) | 2011-12-27 |
| CN1934448A (zh) | 2007-03-21 |
| NZ540719A (en) | 2009-07-31 |
| KR20050083941A (ko) | 2005-08-26 |
| HK1075936A1 (en) | 2005-12-30 |
| EP1563301B1 (de) | 2011-09-14 |
| AU2003294482A1 (en) | 2004-06-15 |
| EP1563301A2 (de) | 2005-08-17 |
| WO2004045559A2 (en) | 2004-06-03 |
| CN1934448B (zh) | 2012-01-11 |
| IL168651A (en) | 2011-04-28 |
| AP2005003332A0 (en) | 2005-06-30 |
| WO2004045559A3 (en) | 2004-08-12 |
| AP1925A (en) | 2008-12-08 |
| ZA200504053B (en) | 2006-07-26 |
| CA2506696A1 (en) | 2004-06-03 |
| CA2506696C (en) | 2013-05-14 |
| AU2003294482A2 (en) | 2005-08-25 |
| ATE524735T1 (de) | 2011-09-15 |
| EP1563301A4 (de) | 2007-07-11 |
| JP2006508988A (ja) | 2006-03-16 |
| BR0316423A (pt) | 2005-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120156245A1 (en) | Methods for the Prevention of Malaria | |
| Vaughan et al. | Genetically engineered, attenuated whole-cell vaccine approaches for malaria | |
| Scheller et al. | Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. | |
| Thera et al. | Vaccines for malaria: how close are we? | |
| Doolan et al. | DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation | |
| Van Braeckel-Budimir et al. | CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model | |
| Hassert et al. | Memory CD8+ T cell‐mediated protection against liver‐stage malaria | |
| Healer et al. | Vaccines to accelerate malaria elimination and eventual eradication | |
| Mikolajczak et al. | Preerythrocytic malaria vaccine development | |
| Shital et al. | An update on recombinant vaccines against leishmaniasis | |
| García-Basteiro et al. | Approaching the target: the path towards an effective malaria vaccine | |
| Gardner et al. | DNA vaccines against malaria: immunogenicity and protection in a rodent model | |
| US20050220822A1 (en) | Methods for the prevention of malaria | |
| Druilhe et al. | Pre-erythrocytic stage malaria vaccines: time for a change in path | |
| Syaifudin et al. | The feasibility of gamma irradiation for developing malaria vaccine | |
| Borkens | Malaria & mRNA vaccines: A possible salvation from one of the most relevant infectious diseases of the global south | |
| EP1563301B1 (de) | Impfstoff zur vorbeugung gegen malaria | |
| Todryk et al. | Building better T‐cell‐inducing malaria vaccines | |
| Verma et al. | Malaria vaccines: current developments and immunological insights | |
| Hedstrom et al. | The development of a multivalent DNA vaccine for malaria | |
| Serrano‐Coll et al. | Plasmodium and host immunity: evasion strategies and advances in malaria vaccination | |
| Good | Our impasse in developing a malaria vaccine | |
| HK1075936B (en) | Vaccine for the prevention of malaria | |
| Kristoff | Malaria stage-specific vaccine candidates | |
| Bashir et al. | Unveiling Malaria Vaccine Miracle |